Aileron Therapeutics, Inc.

ALRN

US00887A2042

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 07:03:28 17/07/2024 pm IST			5-day change	1st Jan Change
3.11 ^USD	+0.65%		-2.22%	+1.36%

01/07	Aileron Therapeutics, Inc.(NasdaqCM:ALRN) added to Russell 3000E Index	CI
01/07	Aileron Therapeutics, Inc.(NasdaqCM:ALRN) added to Russell Microcap Index	CI

Aileron Therapeutics, Inc. announced that it has received $30.112894 million in funding

January 06, 2017

On January 6, 2017, Aileron Therapeutics, Inc. closed the transaction. The company has received $30,112,894 in the transaction from 11 investors.

Latest news about Aileron Therapeutics, Inc.

Aileron Therapeutics, Inc.(NasdaqCM:ALRN) added to Russell 3000E Index	01/07	CI
Aileron Therapeutics, Inc.(NasdaqCM:ALRN) added to Russell Microcap Index	01/07	CI
Aileron Therapeutics, Inc.(NasdaqCM:ALRN) added to Russell Microcap Growth Index	01/07	CI
Aileron Therapeutics, Inc.(NasdaqCM:ALRN) added to Russell 3000E Growth Index	01/07	CI
Certain Warrants of Aileron Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 18-JUN-2024.	18/06	CI
Certain Common Stock of Aileron Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 18-JUN-2024.	18/06	CI
Aileron Therapeutics, Inc. Announces Chief Financial Officer Changes	17/05	CI
Aileron Therapeutics, Inc. Announces Executive Changes	17/05	CI
Aileron Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	16/05	CI
Aileron Therapeutics Closes Direct Offering of Shares, Warrants	04/05	MT
Transcript : Aileron Therapeutics, Inc. - Special Call	01/05
Aileron Therapeutics, Inc. Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis	01/05	CI
Ladenburg Thalmann Adjusts Aileron Therapeutics Price Target to $19 From $9, Maintains Buy Rating	18/04	MT
Aileron Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	16/04	CI
Aileron Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	16/04	CI
Aileron Therapeutics, Inc. Announces CFO Changes	29/03	CI
Aileron Therapeutics, Inc. Announces Board Changes	29/03	CI
Aileron Therapeutics Names Brian Windsor as CEO	12/03	MT
Aileron Therapeutics, Inc. Announces Appointment of Brian Windsor as President and to the Board of Directors	12/03	CI
Aileron Therapeutics, Inc. Announces CEO Changes	12/03	CI
Aileron Therapeutics, Inc. Announces Resignation of Nolan Sigal, M.D., Ph.D. from Board of Directors, Member of Nominating and Corporate Governance Committee	02/03	CI
Transcript : Aileron Therapeutics, Inc. - Special Call	16/02
North American Morning Briefing : Stock Futures, -2-	04/12	DJ
Ladenburg Thalmann Upgrades Aileron Therapeutics to Buy From Neutral, Price Target is $9	01/12	MT
Transcript : Aileron Therapeutics, Inc., Lung Therapeutics, Inc. - M&A Call	31/23/31

Chart Aileron Therapeutics, Inc.

Duration

Period

More charts

Aileron Therapeutics, Inc. is a biopharmaceutical company. The Company is advancing a pipeline of medicines to address unmet medical needs in orphan pulmonary and fibrosis indications. Its lead product candidate, LTI-03, is a synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. LTI-03 is being evaluated in a Phase Ib clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate, LTI-01, is a proenzyme, or zymogen, designed to slowly activate in the pleural space and break up the scar tissue, allowing for drainage of the pleural effusion. It has completed Phase Ib and Phase IIa clinical trials for the treatment of loculated pleural effusions.

Sector

Biotechnology & Medical Research

Calendar

07/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.09 USD

Average target price

13 USD

Spread / Average Target

+320.71%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
AILERON THERAPEUTICS, INC.	+1.36%	6.68Cr
VERTEX PHARMACEUTICALS INCORPORATED	+20.17%	13TCr
REGENERON PHARMACEUTICALS, INC.	+24.67%	12TCr
ARGENX SE	+24.37%	2.79TCr
BIONTECH SE	-17.74%	2.1TCr
GENMAB A/S	-15.78%	1.69TCr
BEIGENE, LTD.	-15.21%	1.62TCr
NEUROCRINE BIOSCIENCES, INC.	+11.91%	1.48TCr
WUXI APPTEC CO., LTD.	-47.10%	1.48TCr
SAREPTA THERAPEUTICS, INC.	+54.50%	1.41TCr

Bio Therapeutic Drugs